CTLA4 and neoplasm: In our study, the tumor response assessed at 3 months using imPERCIST 5 and PERCIST5 PET/CT criteria in patients with advanced or metastatic melanoma treated with first-line anti-PD1 +/−anti CTLA4 combination is a predictor of OS.